Sort   by:  
 Page size 
MetabolomicsTargeting CRBN to alter CD8 T cell metabolism
Not available
ORGANISM(S): Mus musculus 
ST000307 | MetabolomicsWorkbench
GenomicsProteome-wide identification of the druggable CRBN interactome
Proteome-wide identification of the druggable CRBN interactome
PRJNA1271326 | ENA
ProteomicsCRL4(CRBN) ubiquitin ligase profiling
In the 1950s the drug thalidomide administered as a sedative to pregnant women led ot the birth of thousands of children with multiple defects. Despite its teratogenicity, thalidomide and ist IMiD derivatives recently emerged as effective treatments for multiple myeloma and 5q-dysplasia. IMiDs targe...
ORGANISM(S): Homo sapiens 
2014-05-13 | E-GEOD-57554 | biostudies-arrayexpress
ProteomicsThe IMiD receptor CRBN determines quality control of transmembrane proteins
The complex architecture of transmembrane proteins requires quality control (QC) for folding and membrane positioning, a prerequisite for cellular homoeostasis and intercellular communication. However, it has remained unclear whether transmembrane proteins-specific QC hubs exist. Here we specify Cer...
ORGANISM(S): Homo sapiens (Human) 
2021-02-18 | PXD018244 | Pride
Imids Chaperones Membrane proteins Lumos Human Multiple myeloma 
ProteomicsDegron-independent recruitment of KAT2A redefines the breadth of CRBN-based molecular-glue targets
Lysine acetyltransferases (KATs) frequently cooperate with oncogenes such as c-Myc, estrogen receptor, and KMT2A-fusions to sustain malignant programs. Therapeutic targeting of KAT proteins has shown clinical efficacy, yet achieving homolog-selectivity for most KATs remains a major challenge. Here, ...
ORGANISM(S): Homo sapiens (Human) 
2026-08-29 | PXD072306 | Pride
Ubiquitin Kat2a Crbn Molecular glue Lysine acetyltransferases Protein degradation E3 ligase Aml 
OtherProteome-wide identification of the druggable CRBN interactome
Molecular glue degraders (MGDs), such as pomalidomide, induce degradation of non-native substrates by the E3 ligase CRL4CRBN through its substrate receptor CRBN. To explore CRBN programmability, we tested whether reported CRBN-MGD substrates are part of a network of latent CRBN interactors, proteins...
ORGANISM(S): Saccharomyces cerevisiae 
2026-06-08 | GSE298800 | GEO
GenomicsRNA-Seq identifies alternative splicing of CRBN induced by ILF3 KO
RNA-Seq identifies alternative splicing of CRBN induced by ILF3 KO
PRJNA645653 | ENA
ProteomicsCRL4(CRBN) ubiquitin ligase profiling
In the 1950s the drug thalidomide administered as a sedative to pregnant women led ot the birth of thousands of children with multiple defects. Despite its teratogenicity, thalidomide and ist IMiD derivatives recently emerged as effective treatments for multiple myeloma and 5q-dysplasia. IMiDs targe...
ORGANISM(S): Homo sapiens 
2014-05-13 | GSE57554 | GEO
ProteomicsDegron-independent recruitment of KAT2A redefines the breadth of CRBN-based molecular-glue targets
Lysine acetyltransferases (KATs) frequently cooperate with oncogenes such as c-Myc, estrogen receptor, and KMT2A-fusions to sustain malignant programs. Therapeutic targeting of KAT proteins has shown clinical efficacy, yet achieving homolog-selectivity for most KATs remains a major challenge. Here, ...
ORGANISM(S): Homo sapiens (Human) 
2026-08-29 | PXD072361 | Pride
ProteomicsPCMT1 generates the C-terminal cyclic imide degron on CRBN substrates
The E3 ligase substrate adapter cereblon (CRBN), the primary target of clinical agents thalidomide and lenalidomide, recognizes endogenous substrates bearing the C-terminal cyclic imide modification. Although C-terminal cyclic imides can form spontaneously, an enzyme that regulates the formation of ...
ORGANISM(S): Mus musculus (Mouse) Homo sapiens (Human) 
2025-12-05 | PXD061730 | Pride
Crbn Pcmt1 C-terminal cyclic imide Glul Ppa1 
Sort   by:  
 Page size